US EditionOzempic in a pill? The next generation of weight-loss drugs emerges
- GLP-1 and incretin-based drugs have created the largest class of weight-loss drugs ever, according to Garron Dodd, a researcher at the University of Melbourne.
- A phase 3 trial showed that a once-weekly semaglutide dose led to a 14.9 percent weight loss over 15 months.
- Eli Lilly plans to apply for regulatory approval for its new obesity drug later this year after positive trial results.
- These drugs might revolutionize health-span, according to Garron Dodd, who referred to it as 'a glorious dawn'.
18 Articles
18 Articles
Novo Nordisk and Eli Lilly, which dominate the global market for obesity drugs, now have their first serious rival in China.
In a quick search on the internet, you will immediately find several options to buy Mounjaro, a novel drug that, according to its creators, is better than Ozempic to lose weight. "I sell insulin Mounjaro. I have four of 5 mg/0.5 mL", read in a publication where it is offered at 1.800 pesos, price similar to that which you have in some commercial pharmacies that present it as an uncontrolled medicine and that does not require a prescription for s…
Sydney Morning Herald
Ozempic in a pill? The next generation of weight-loss drugs emerges
Rochelle McDonald has just been through the messiest of break-ups. “Guzman y Gomez were devastated,” she says, but 17 kilos lighter, she’s laughing.
A 'Chronicle' reporter accesses the site where Ozempic and Wegovy are manufactured, the most advanced drugs against type 2 diabetes and obesity. At the technological epicenter of the Danish pharmaceutical industry, a battalion of robots and humans produce drugs that have become the object of desire, hope and controversy worldwide. Read
FDA Accepts Application for Oral Version of Wegovy
The US Food and Drug Administration (FDA) recently accepted a new drug application for oral semaglutide. If approved, it would be the first oral glucagon-like peptide-1 (GLP-1) receptor agonist authorized for long-term weight management. The 25-mg semaglutide pill would be marketed as Wegovy, the same name used for Novo Nordisk’s FDA-approved 2.4-mg semaglutide injection.
Coverage Details
Bias Distribution
- 50% of the sources lean Right
To view factuality data please Upgrade to Premium
